Ipsen S.A. Reports Strong First-Half Performance and Raises Fiscal Year 2026 Guidance
Ipsen S.A., a French biopharmaceutical company, reported first-half non-GAAP earnings per share (EPS) of €7.33 with revenue reaching €2.19 billion, representing a year-over-year increase of 20.3%. The firm's core operating income rose to €845 million, up by 28.8%, while the core operating margin expanded to 38.6% of total sales, an improvement of 2.5 percentage points. The strong performance has led Ipsen S.A. to upgrade its financial guidance for fiscal year 2026, signaling confidence in continued growth and operational efficiency improvements.
Topics: eps guidance operating_income revenue